FARON.HE Faron Pharmaceuticals Oy
- Market cap
- EUR 77.7M
- P/E
- -
- P/B
- 6.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is FARON.HE undervalued?
Graham numberThe Graham number of Faron Pharmaceuticals Oy cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Faron Pharmaceuticals Oy fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-235.8%), below 10%.
ROA 0/1
Return on assets (-76.1%) is below the industry median (-19.8%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (3.8%) is below the industry median (3.8%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (79.8%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 1/2
Cash covers 1.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (6.6x) is above the industry median (3.1x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Faron Pharmaceuticals Oy stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combina…
Full company profileFaron Pharmaceuticals Oy financial statements
Faron Pharmaceuticals Oy annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.1M | -16.7M | -21.1M | -27.4M | -28.6M | -18.7M | -19.0M |
| EBITDA | -12.8M | -16.3M | -20.6M | -27.1M | -28.5M | -21.7M | -25.7M |
| Net Income | -13.3M | -16.9M | -21.2M | -28.7M | -30.9M | -25.9M | -27.3M |
| EPS | -0.31 | -0.36 | -0.33 | -0.37 | -0.34 | -0.23 | -0.22 |
| Balance Sheet | |||||||
| Total Assets | 10.2M | 8.37M | 13.2M | 11.3M | 10.2M | 12.5M | 17.2M |
| Total Liabilities | 8.60M | 10.2M | 10.3M | 22.7M | 25.4M | 22.3M | 35.7M |
| Shareholders' Equity | 1.61M | -1.85M | 2.92M | -11.5M | -15.2M | -9.76M | -18.5M |
| Cash & Short-term Investments | 7.06M | 4.11M | 6.85M | 6.99M | 6.88M | 9.50M | 12.3M |
| Cash Flow | |||||||
| Operating Cash Flow | -11.5M | -17.5M | -22.2M | -23.0M | -23.8M | -22.3M | -17.9M |
| Capital Expenditure | 100K | 142K | 474K | 385K | 123K | 226K | 222K |
| Free Cash Flow | -11.6M | -17.6M | -22.7M | -23.4M | -23.9M | -22.5M | -18.1M |
| Ratios | |||||||
| ROE | -823.7% | - | -726.1% | - | - | - | - |
| ROA | -129.9% | -202.5% | -160.8% | -254.9% | -302.8% | -207.0% | -158.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Faron Pharmaceuticals Oy dividends
Faron Pharmaceuticals Oy has not paid dividends in the last 7 fiscal years.
Who owns Faron Pharmaceuticals Oy
- Insiders 16.17%
- Institutions 21.05%
- Public & others 62.78%
- Shares outstanding 203M
- Free float 137M
Faron Pharmaceuticals Oy company profile
- Company name
- Faron Pharmaceuticals Oy
- Ticker
- FARON.HE
- Exchange
- Helsinki Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 36
- Fiscal year end
- December
- Address
- Joukahaisenkatu 6 B, Turku, Finland, 20520
- Phone
- 358 2469 5151
- Website
- faron.com
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Faron Pharmaceuticals Oy management
7- Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.Founder, CEO & Director · born 1978
- Mr. Jurriaan DekkersChief Financial Officer · born 1976
- Mr. Heikki JouttijarviChief Technical Officer
- Dr. Maija Hollmen Ph.D.Chief Scientific Officer
- Mr. Vesa Karvonen L.L.M.General Counsel · born 1972
- Dr. Petri Bono M.D., Ph.D.Chief Medical Officer · born 1970
- Mr. Ralph HughesChief Business Officer